H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aravive to $12 from $7 and keeps a Buy rating on the shares following the Q4 report. The company ended the year with $53.7M in cash, which management believes will be sufficient to sustain ongoing operations into the first half of 2024, the analyst tells investors in a research note. The firm says the Aravive continued to progress its clinical development activities in 2022, with key readouts approaching in 2023.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARAV:
- Aravive expects cash to sustain operations into Q4
- Aravive reports Q4 EPS (46c), consensus (30c)
- Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
- Aravive receives orphan drug designation for batiraxcept from FDA
- 2 “Strong Buy” Penny Stocks With Multibagger Potential